DIA RSIDM 2026: From Doing Digital to Being Data-Driven

There is massive interest in GenAI, but blind automation is not an option. The industry is moving toward a “Human-in-the-Loop” ecosystem.

• The Shift: We are moving from de novo creation to a review-and-refine workflow.
• The Goal: AI acts as a sophisticated assistant for drafting and Quality Control, allowing professionals to focus on strategy rather than formatting.

Spreadsheets and static PDFs still dominate our landscape, creating compliance risks and hindering speed. To fix this, the industry is pushing toward “Integrated Regulatory Hubs” and “Canonical Data Models.”

• The Objective: Treat data as a product that is FAIR (Findable, Accessible, Interoperable, Reusable).
• The Method: Move to structured content management, where data elements are authored once and reused across multiple submissions.

The current submission model is antiquated. It relies on unidirectional communication that creates latency.

• The Future: A shift toward bi-directional, real-time data exchange via cloud-based platforms and eCTD 4.0.
• The Benefit: Health Authorities can question specific data points, and sponsors can correct data without resubmitting entire documents.

Regulatory professionals must prepare for specific technical and operational shifts over the next year and a half.

The shift to a newest version of the eCTD standard (from v3.2.2 to v4.0) is a logic change, not just a format change. Teams need to assess publishing tools and understand the new context of use for documents involving unique identifiers.

Sponsors cannot simply buy AI tools; they must validate them. There is an immediate need to define “acceptable use” and ensure that decision -making remains in human hands.

You cannot build AI on top of data chaos. To ensure regulatory compliance, companies must now standardize their internal product information to meet ISO IDMP requirements, which act as a global “digital language” for identifying medicinal products consistently across all regions. This “data cleaning” is essential to transition away from static PDF documents and toward the PQ-CMC initiative, which requires pharmaceutical quality and manufacturing details to be submitted as searchable, structured data. By organizing this information now, firms can ensure their eCTD submissions are compatible with the automated review systems being adopted by the FDA and EMA.

Based on collective insights from the conference, RegOps teams should focus on three priorities.

Stop treating Regulatory Information Management (RIM) as just a tracking tool. Invest in a strategy that connects RIM with Clinical, Quality, and Safety systems. Implement a canonical data model to ensure that core data is defined once and reused everywhere. This is the only way to enable future automation.

Do not start with full submission authoring. Begin by deploying AI agents for tasks like Regulatory Intelligence, Automated QC, and Legacy Data Extraction. These use cases offer immediate ROI with lower compliance risk.

Move the RegOps team away from publishing and archiving toward data stewardship and strategy. Train staff on data lineage, basic analytics, and prompt engineering. The future RegOps professional will need to manage data flows and content supply chains rather than just compiling documents.

DIA RSIDM 2026 highlighted that the shift from going digital to being data-driven directly impacts clinical operations execution. Continued reliance on document-based processes, fragmented clinical trial data, and manual handoffs slows trial delivery, increases inspection risk, and limits the effective use of analytics and AI.

In the coming months, organizations must focus on structured clinical data, data governance, and stronger alignment between clinical operations, data management, and regulatory teams. AI adoption in clinical development depends on reliable source data, clear data ownership, and validated workflows that support trial oversight, Trial Master File (TMF) completeness, and inspection readiness.

Clinical operations teams that invest in data standardization and integrated workflows will be better positioned to support efficient trial execution, regulatory submissions, and ongoing compliance—without adding operational burden.

Now that DIA RSIDM 2026 is behind us, clinical operations teams must turn their focus to the data, workflow, and execution challenges ahead.